PROPANC BIOPHARMA, INC. Debt Instrument, Face Amount
PROPANC BIOPHARMA, INC. (PPCB) had Debt Instrument, Face Amount of $145.65 thousand as of 2026-03-31, per its S-1 filed 2026-07-17.
Financial Statements › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFaceAmount · last filed 2026-07-17
- 2026-03-31: Debt Instrument, Face Amount $145.65K.
- 2025-12-31: Debt Instrument, Face Amount $145.65K.
- 2025-09-30: Debt Instrument, Face Amount $69.65K.
- 2025-06-30: Debt Instrument, Face Amount $54.85K.
USD
| Period end | Debt Instrument, Face Amount | Debt Instrument, Face Amount as first filed |
|---|---|---|
| 2026-03-31 | $145.65K S-1 · filed 2026-07-17 | |
| 2025-12-31 | $145.65K S-1 · filed 2026-04-10 | |
| 2025-09-30 | $69.65K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $54.85K S-1 · filed 2026-07-17 | |
| 2025-03-31 | $70.31K S-1 · filed 2026-07-17 | $54.85K 10-Q · filed 2025-05-15 |
| 2024-12-31 | $49.10K 10-Q · filed 2025-02-14 | |
| 2024-09-30 | $30.80K 10-Q · filed 2024-11-14 | |
| 2024-08-31 | $57.64K S-1 · filed 2026-07-17 | |
| 2024-06-30 | $130.80K S-1 · filed 2026-07-17 | |
| 2024-05-31 | $71.63K S-1 · filed 2026-07-17 | |
| 2024-03-31 | $91.30K 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $75.30K 10-Q · filed 2024-02-20 | |
| 2023-11-30 | $71.63K S-1 · filed 2026-07-17 | |
| 2023-09-30 | $70.80K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $168.20K 10-K · filed 2024-09-30 | |
| 2022-12-31 | $125.00K 10-Q · filed 2023-02-10 | |
| 2022-09-30 | $79.00K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $1.00K 10-K · filed 2023-09-28 | |
| 2021-06-30 | $95.00K 10-K · filed 2022-09-28 | |
| 2020-11-30 | $19.60K 10-K · filed 2022-09-28 | |
| 2020-09-30 | $19.60K 10-Q · filed 2021-05-14 | |
| 2020-01-02 | $267.19K 10-Q · filed 2020-02-14 | |
| 2017-12-31 | $340.18K 10-Q · filed 2018-02-09 | |
| 2017-09-30 | $577.77K 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $911.00 10-K · filed 2017-09-28 | |
| 2017-03-31 | $911.00 10-Q · filed 2017-05-08 | |
| 2017-01-02 | $490.18K 10-Q · filed 2018-02-09 | |
| 2016-06-30 | $2.80M 10-Q · filed 2018-02-09 | |
| 2016-05-19 | $375.00K 10-Q · filed 2017-11-09 | |
| 2016-03-16 | $1.20M 10-Q · filed 2017-11-09 | |
| 2015-12-10 | $27.50K 10-K · filed 2017-09-28 | |
| 2015-10-28 | $4.00M 10-Q · filed 2017-02-14 | |
| 2015-06-04 | $269.98K 10-Q · filed 2018-02-09 | |
| 2014-08-06 | $250.00K 10-K · filed 2016-09-28 | |
| 2014-07-31 | $628.00K 10-Q · filed 2015-02-17 |
AUD
| Period end | Debt Instrument, Face Amount | Debt Instrument, Face Amount as first filed |
|---|---|---|
| 2024-08-31 | 85.00K AUD S-1 · filed 2026-07-17 | |
| 2023-11-30 | 71.63K AUD 10-K · filed 2024-09-30 | 16.43K AUD 10-Q · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |